证券代码：600873 证券简称：梅花生物 公告编号：2023-052 梅花生物科技集团股份有限公司 关于2023年半年度经营数据公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 3、按地区分： | 地区分布 | 本期营业收入（万元） | | --- | --- | | 国内 | 939,772.42 | | 国外 | 419,054.63 | | 合计 | 1,358,827.05 | 特此公告。 根据《上市公司行业信息披露指引第十四号—食品制造》第十四条、《关于 做好主板上市公司 2023 年半年度报告披露工作的重要提醒》的要求，现将梅花 生物科技集团股份有限公司 2023年半年度经营数据（未经审计）公告如下： 1、按产品分： | 产品类别 | 本期营业收入（万元） | | --- | --- | | 鲜味剂（谷氨酸钠、核苷酸） | 444,567.07 | | 饲料氨基酸（赖氨酸、苏氨酸、色氨酸等） | 475,820.72 | | 医药氨基酸（谷氨酰胺、脯氨酸、亮氨酸、异亮氨酸、腺苷等） | 29,991.59 ...

证券代码：600873 证券简称：梅花生物 公告编号：2023-053 梅花生物科技集团股份有限公司 关于 2021 年员工持股计划存续期 即将届满的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 梅花生物科技集团股份有限公司（以下简称"公司"）分别于 2021 年 1 月 14 日、2021 年 2 月 1 日召开了第九届董事会第十四次会议和 2021 年第一次临时股 东大会，会议审议通过了《关于公司 2021 年员工持股计划（草案）及其摘要的 议案》等相关议案。 公司分别于 2021 年 1 月 14 日、2021 年 2 月 1 日召开了第九届董事会第十 四次会议和 2021 年第一次临时股东大会，会议审议通过了《关于公司 2021 年员 工持股计划（草案）及其摘要的议案》、《关于公司 2021 年员工持股计划管理办 法的议案》、《关于提请股东大会授权董事会全权办理公司员工持股计划相关事项 的议案》等相关议案，具体内容详见公司于 2021 年 1 月 15 日、2021 年 2 月 2 日在上海证券交易 ...

特此公告。 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 梅花生物科技集团股份有限公司（以下简称"公司"）分别于 2023 年 4 月 8 日、2023 年 4 月 28 日召开了第十届董事会第三次会议和 2023 年第二次临时股 东大会，会议审议通过了《关于以集中竞价交易方式回购公司股份的议案》，公 司于 2023 年 4 月 29 日披露了《梅花生物科技集团股份有限公司关于以集中竞价 交易方式回购股份的回购报告书》，本次回购金额不低于人民币 8 亿元，不超过 人民币 10 亿元，回购股份用于注销，减少注册资本。具体内容详见公司披露在 上海证券交易所网站（www.sse.com.cn）上的相关公告。 现将公司回购股份进展的具体情况公告如下： 证券代码：600873 证券简称：梅花生物 公告编号：2023-050 截至 2023 年 8 月 14 日，公司回购股份 2,033.29 万股，占公司目前股本总数 (2,943,426,102 股)的 0.69%，购买的最低价格为 8.77 元/股、最高价格为 9.15 元/ ...

Financial Performance - The company's operating revenue for Q1 2023 was RMB 6,950,072,385.57, representing a year-on-year increase of 3.54%[4] - The net profit attributable to shareholders for Q1 2023 was RMB 800,793,127.47, a decrease of 30.89% compared to the same period last year, primarily due to a decline in gross margin from 26.24% to 19.84%[6] - Basic and diluted earnings per share for Q1 2023 were both RMB 0.26, reflecting a decrease of 29.73% year-on-year[4] - Total revenue for Q1 2023 reached RMB 6,950,072,385.57, an increase of 3.54% compared to RMB 6,712,290,632.48 in Q1 2022[16] - Operating profit for Q1 2023 is approximately ¥945.13 million, down 30.5% from ¥1.36 billion in the same period last year[17] - The net profit for Q1 2023 is approximately ¥800.79 million, a decrease of 30.9% compared to ¥1.16 billion in Q1 2022[17] - Earnings per share for Q1 2023 is ¥0.26, down from ¥0.37 in Q1 2022[17] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 54.20% to RMB 333,494,806.92, mainly due to increased raw material purchases[6] - Cash flow from operating activities for Q1 2023 is approximately ¥333.49 million, a decrease of 54.3% compared to ¥728.21 million in Q1 2022[18] - Cash flow from investing activities shows a net outflow of approximately ¥969.36 million in Q1 2023, slightly higher than the outflow of ¥965.77 million in Q1 2022[19] - Cash flow from financing activities results in a net outflow of approximately ¥217.90 million in Q1 2023, compared to a net outflow of ¥107.41 million in Q1 2022[19] - The company raised approximately ¥640 million in new borrowings in Q1 2023, significantly higher than ¥210 million in Q1 2022[19] - The company's cash and cash equivalents decreased to RMB 3,450,756,112.91 from RMB 4,333,600,657.71 year-over-year[13] - The total cash and cash equivalents at the end of Q1 2023 is approximately ¥3.27 billion, an increase from ¥2.90 billion at the end of Q1 2022[19] Assets and Liabilities - Total assets at the end of Q1 2023 were RMB 24,527,015,822.15, a slight increase of 0.15% from the end of the previous year[4] - The company's total assets amounted to RMB 24,527,015,822.15, slightly up from RMB 24,490,222,471.46 at the end of Q1 2022[15] - Total liabilities increased to RMB 11,599,502,934.70, compared to RMB 10,974,089,118.69 in Q1 2022, reflecting a growth of 5.69%[15] - The company's equity attributable to shareholders decreased to RMB 12,927,512,887.45 from RMB 13,516,133,352.77 in the previous year, a decline of 4.35%[15] - Short-term borrowings rose to RMB 1,324,462,695.04, an increase of 23.6% from RMB 1,070,498,635.74 in Q1 2022[15] - The total non-current liabilities decreased to RMB 3,916,073,176.45 from RMB 4,301,661,573.36, a reduction of 8.93%[15] Shareholder Information - The top shareholder, Meng Qingshan, holds 28.07% of the shares, with a total of 854,103,033 shares[7] - The company completed a share buyback of 99,039,345 shares, accounting for 3.26% of the total share capital at that time, with an average repurchase price of RMB 10.09 per share[11] - The company has initiated a new employee stock ownership plan, purchasing 28,260,800 shares for a total of RMB 295,296,438, representing 0.93% of the total share capital[11] - The company plans to continue implementing share buybacks in accordance with regulatory requirements[11] Strategic Focus and Growth - The increase in operating revenue was mainly driven by growth in sales of flavoring agents and xanthan gum products[6] - The company’s strategic focus includes enhancing its market position through potential mergers and acquisitions, although specific targets were not disclosed[11] - Research and development expenses increased to RMB 70,825,927.68, a rise of 19.93% from RMB 59,037,845.21 in the same period last year[16]

Financial Performance - The company's operating revenue for 2022 was approximately ¥27.94 billion, an increase of 21.14% compared to ¥23.06 billion in 2021[14]. - Net profit attributable to shareholders for 2022 reached approximately ¥4.41 billion, representing an 83.42% increase from ¥2.40 billion in 2021[14]. - The net profit after deducting non-recurring gains and losses was approximately ¥4.22 billion, up 101.69% from ¥2.09 billion in the previous year[14]. - The net cash flow from operating activities for 2022 was approximately ¥5.65 billion, a 51.43% increase from ¥3.73 billion in 2021[14]. - The total assets of the company at the end of 2022 were approximately ¥24.49 billion, reflecting a 16.73% increase from ¥20.98 billion at the end of 2021[14]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥13.52 billion, a 26.64% increase from ¥10.67 billion at the end of 2021[14]. - The company achieved a total revenue of 27.937 billion RMB, representing a year-on-year growth of 21.14%[23]. - The basic earnings per share rose to 1.44 RMB, up 84.62% from 0.78 RMB in 2021[16]. - The weighted average return on equity increased to 35.95%, up 9.18 percentage points from the previous year[24]. - The company maintained a reasonable debt-to-asset ratio of 44.81%[24]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of ¥4.0 per 10 shares, totaling approximately ¥1.22 billion, subject to shareholder approval[2]. - The company declared a cash dividend of RMB 1,216,986,178.8, which accounts for 27.62% of the net profit attributable to shareholders[112]. - The total dividend amount, including cash dividends and share repurchases, reached RMB 2,117,601,589.9, representing 48.06% of the net profit attributable to shareholders[112]. Research and Development - The company introduced a significant number of high-educated talents to strengthen its R&D and engineering teams[23]. - R&D expenses amounted to CNY 829 million, representing a 9.73% increase from the previous year, attributed to increased investment in R&D projects[39]. - The company implemented a dual-driven strategy focusing on technology and management, with significant investments in research and development to maintain industry leadership[26]. - In 2022, the company authorized 27 invention patents, including 2 patents authorized in Japan, and filed 12 new patents[27]. Market and Product Development - The company aims to extend its pharmaceutical amino acids product line to downstream and end products, positioning itself as a leading expert and solution provider in the industry[28]. - The company's market share for adenosine has increased to approximately 70%, while proline's market share has expanded to 60%[29]. - The company has established partnerships with Danone and Nestlé in the special medical food sector, anticipating continued growth in demand[29]. - The company plans to launch a new xanthan gum project in Jilin Baicheng in the first half of 2023[28]. Operational Efficiency - The company maintained an inventory turnover period of approximately 60 days and accounts receivable turnover days of under 10 days, indicating high operational efficiency[36]. - The company has implemented standardized management practices, resulting in a 50% increase in efficiency for finished product and raw material vehicle processing times[30]. - The company achieved a 30% improvement in efficiency for corn transport from factory entry to exit[30]. Environmental and Social Responsibility - The company invested approximately 256.85 million yuan in environmental protection during the reporting period[124]. - The company has established a sustainable development management system and a three-year enhancement plan focusing on ESG (Environmental, Social, and Governance) strategies[81]. - The company is committed to sustainability, with plans to reduce carbon emissions by 20% over the next five years through improved operational efficiencies[88]. - The company has implemented an automatic monitoring system for wastewater and air emissions, ensuring accurate and timely data reporting[133]. Risk Management - The company faces risks from significant fluctuations in raw material prices, particularly corn and coal, which could adversely affect overall gross margins[76]. - The company is exposed to macroeconomic risks, including potential declines in consumer demand due to economic slowdowns or public health crises[77]. - The company is at risk from geopolitical tensions, particularly between the U.S. and China, which could impact its export business[78]. Corporate Governance - The company has established specialized committees under the board, including the remuneration and assessment committee, which is responsible for overseeing executive compensation[99]. - The company has not faced any penalties from securities regulatory agencies in the past three years[95]. - The company conducted a special audit of accounts receivable and accounts payable, leading to a comprehensive review and improvement of internal control processes in sales and procurement[81]. Share Buybacks and Equity Management - The company completed a share buyback of 26,084,878 shares, accounting for 0.84% of the total shares, with an average buyback price of 7.68 CNY per share, totaling 200.20 million CNY[178]. - The company plans to cancel the remaining repurchased shares, reducing its registered capital accordingly[182]. - The total number of shares held by directors and senior management at the end of the reporting period was 148,948,150, a decrease of 990,300 shares compared to the beginning of the year[87]. Audit and Compliance - The audit opinion confirmed that the financial statements fairly reflect the company's financial position as of December 31, 2022[193]. - Revenue recognition was identified as a key audit matter due to inherent risks of manipulation[195]. - The auditor evaluates the appropriateness of accounting policies and the reasonableness of accounting estimates made by management[197].

证券代码：600873 证券简称：梅花生物 公告编号：2023-014 梅花生物科技集团股份有限公司 关于召开2022年度业绩说明会的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 03 月 09 日(星期四)下午 14:00-15:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 03 月 02 日(星期四)至 03 月 08 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 mhzqb@meihuagrp.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 梅花生物科技集团股份有限公司（以下简称"公司"）将于 2023 年 3 月 7 日在上海证券交易所网站（http://www.sse.com.cn/）披露 2022 年年度报告，为便 于广大投资者更全面深入地了解公司 2022 年年度 ...

Financial Performance - Revenue for Q3 2022 reached ¥6,601,538,523.32, a 25.55% increase compared to ¥5,258,021,313.79 in the same period last year[4] - Net profit attributable to shareholders was ¥868,244,074.94, representing a 168.95% increase from ¥322,829,844.65 year-on-year[4] - Net profit excluding non-recurring gains and losses was ¥854,513,403.83, up 185.29% from ¥299,523,886.60 in the previous year[4] - Basic earnings per share for Q3 2022 was ¥0.28, a 180.00% increase from ¥0.10 in the same quarter last year[4] - Diluted earnings per share also stood at ¥0.28, reflecting a 180.00% increase compared to ¥0.10 year-on-year[4] - The weighted average return on equity increased to 6.98%, up 3.53 percentage points from 3.45% in the previous year[4] - The company achieved operating revenue of 6.602 billion RMB in Q3 2022, an increase of 25.55% year-on-year, primarily due to a 30.46% increase in revenue from animal nutrition amino acid products and a 23.66% increase from food flavor optimization products[7] - Net profit attributable to shareholders reached 868 million RMB, a significant increase of 168.95% compared to the same period last year, driven by improved gross margin from 14.9% to 21.79%[7] - The net profit excluding non-recurring items was 855 million RMB, reflecting a year-on-year increase of 185.29% due to substantial growth in net profit[7] - For the first three quarters of 2022, the company reported operating revenue of 20.821 billion RMB, up 27.86% year-on-year, with animal nutrition amino acid products increasing by 34.05%[7] - The net profit attributable to shareholders for the first three quarters was 3.444 billion RMB, an increase of 159.49% year-on-year, with gross margin improving from 17% to 25.33%[7] - Operating profit for the first three quarters was ¥4.01 billion, up from ¥1.60 billion in the same period last year, marking an increase of 150.5%[14] - Earnings per share (EPS) for the first three quarters was ¥1.11, significantly higher than ¥0.43 in the same period last year[15] Cash Flow and Assets - Operating cash flow for the year-to-date period was ¥5,455,580,471.51, a 66.46% increase from ¥3,277,319,871.83 last year[4] - The net cash inflow from operating activities was CNY 5,455,580,471.51, an increase of 66.7% compared to CNY 3,277,319,871.83 in the previous year[16] - Total cash inflow from operating activities amounted to CNY 22,997,408,878.67, up from CNY 16,781,349,140.49, reflecting a growth of 37.5%[16] - Cash outflow for purchasing goods and services was CNY 14,578,608,257.55, compared to CNY 11,608,702,273.41, representing a 25.5% increase[16] - Cash flow from operating activities was ¥22.53 billion, compared to ¥16.52 billion in the same period of 2021, representing a growth of 36.4%[15] - Total current assets increased to ¥8,798,777,198.90 from ¥7,570,836,910.82 as of December 31, 2021, representing a growth of approximately 16.2%[11] - Cash and cash equivalents decreased slightly to ¥3,372,690,209.53 from ¥3,396,202,312.57, a decline of about 0.7%[11] - Accounts receivable rose significantly to ¥373,336,140.56, up from ¥280,597,054.53, marking an increase of approximately 33.1%[11] - Inventory decreased to ¥2,688,212,029.89 from ¥2,992,013,893.38, reflecting a decline of about 10.2%[11] - Total non-current assets increased marginally to ¥13,418,030,948.34 from ¥13,408,613,651.93, showing a growth of approximately 0.1%[12] - Total assets at the end of the reporting period were ¥20,921,200,513.89, a 5.90% increase from ¥22,216,808,147.24 at the end of the previous year[4] Shareholder Information - The company has a total of 95,983 common shareholders as of the end of the reporting period[9] - The largest shareholder, Meng Qingshan, holds 28.07% of the shares, with 854,103,033 shares pledged[9] Expenses and Financial Management - Research and development expenses amounted to ¥198.83 million, slightly up from ¥191.23 million in the previous year, indicating a focus on innovation[14] - Total operating costs increased to ¥16.88 billion, up from ¥14.72 billion, reflecting a rise of 14.7%[14] - The company reported a decrease in financial expenses to ¥53.27 million from ¥140.14 million, indicating improved financial management[14] - The gross profit margin improved, with gross profit reaching ¥4.94 billion, compared to ¥1.56 billion in the previous year[14] - The company experienced a net foreign exchange loss of ¥1.03 million, compared to a loss of ¥748,061.48 in the previous year, indicating a slight improvement in currency management[15] Tax and Employee Payments - The company received tax refunds amounting to CNY 388,233,192.16, compared to CNY 216,507,438.28, which is an increase of 79.3%[16] - Cash paid to employees was CNY 1,021,173,581.78, an increase from CNY 875,837,850.44, representing a growth of 16.6%[16] - The cash outflow for taxes paid was CNY 1,033,536,331.87, significantly higher than CNY 505,071,878.91, indicating a rise of 104.5%[16] Strategic Developments - The company has not reported any significant new strategies or product developments in the current quarter[10]

Financial Performance - The company's operating revenue for the first half of 2022 reached CNY 14.22 billion, an increase of 28.96% compared to CNY 11.03 billion in the same period last year[18]. - Net profit attributable to shareholders was CNY 2.58 billion, representing a significant increase of 156.45% from CNY 1.00 billion year-on-year[18]. - The net cash flow from operating activities was CNY 3.47 billion, up 207.20% from CNY 1.13 billion in the previous year[18]. - The total assets of the company at the end of the reporting period were CNY 23.72 billion, a growth of 13.05% compared to CNY 20.98 billion at the end of the previous year[18]. - The net assets attributable to shareholders increased to CNY 12.00 billion, reflecting a 12.43% rise from CNY 10.67 billion at the end of the previous year[18]. - Basic earnings per share for the first half of 2022 were CNY 0.83, a 159.38% increase from CNY 0.32 in the same period last year[19]. - The weighted average return on equity was 21.37%, up from 10.64% year-on-year, indicating improved profitability[19]. - The company achieved a revenue of CNY 14.22 billion, an increase of 28.96% compared to the same period last year, driven by increased lysine production and rising prices of various products[44]. - The revenue from feed amino acids reached CNY 5.67 billion, up 37.52% year-on-year, while the revenue from flavor enhancers was CNY 4.64 billion, a 22.43% increase[44]. - The operating profit margin improved significantly, with net cash flow from operating activities increasing by 207.20% to CNY 3.47 billion, attributed to higher sales revenue[44][45]. Industry Position and Operations - The company operates in the bio-manufacturing industry, focusing on amino acid products, with production bases in Inner Mongolia, Xinjiang, and Jilin, and R&D centers in Langfang and Shanghai[24]. - The company has developed a full lifecycle chain system for synthetic biology products, achieving industry-leading technical indicators and rapid production capabilities[24]. - In the first half of 2022, the company launched new upgraded strains of glutamic acid, threonine, and guanosine, while a new colloid product, xanthan gum, has officially entered production[25][26]. - The company holds 12 new patents in synthetic biology, including 2 patents authorized in Japan, enhancing its global industry position[26]. - The company has become the largest global supplier of lysine and threonine, benefiting from improved industry competition and rising prices of soybean meal[29]. - Exports of lysine esters and salts increased by 45% year-on-year, while threonine exports grew by 15.9% in the first five months of 2022[29]. - The company is positioned to capitalize on the growing demand for amino acids in various applications, supported by its advanced production capabilities and R&D efforts[25]. Financial Health and Cash Flow - The company's cash and cash equivalents increased to ¥4.64 billion, accounting for 19.58% of total assets, up 36.74% year-on-year due to increased sales revenue[48]. - The company's accounts receivable rose to ¥368.39 million, representing 1.55% of total assets, a 31.29% increase year-on-year attributed to higher sales volume[48]. - The company's total assets for its subsidiary Tongliao Meihua reached ¥6.51 billion, with a net profit of ¥743 million for the first half of 2022[54]. - The company's total assets for its subsidiary Xinjiang Meihua amounted to ¥6.63 billion, generating a net profit of ¥1.03 billion during the same period[54]. - The company's total assets for its subsidiary Jilin Meihua were ¥6.37 billion, with a net profit of ¥511 million as of June 30, 2022[54]. - The company's derivative financial assets increased by 184.63% to ¥6.48 million, reflecting fluctuations in the fair value of forward contracts[48]. - The company's other receivables grew by 67.15% to ¥205.93 million, mainly due to an increase in receivables for export tax refunds[48]. - The company's long-term receivables increased by 91.74% to ¥250,012.17, attributed to higher guarantees for financing leases[48]. Environmental and Social Responsibility - The company established an energy conservation and emission reduction committee to enhance its green manufacturing efforts, increasing investment in environmental protection[57]. - The company has achieved a wastewater closed-loop recycling rate of over 93% at Tongliao, utilizing advanced Dutch water treatment technology with an investment of several hundred million yuan[73]. - The company has implemented a comprehensive pollution control strategy, with emissions of SO2 below 35 mg/m³ and NOX below 50 mg/m³ at Xinjiang, adhering to ultra-low emission standards since 2017[75]. - The company has invested approximately 70 million yuan in environmental protection measures, with an additional annual operating cost of 18 million yuan for new environmental technologies[77]. - The company has successfully completed environmental impact assessments for new projects, including the production of granular L-threonine and nucleic acid residue, with approvals obtained[78]. - The company has established online monitoring systems for emissions, ensuring real-time data upload to environmental authorities[75]. - The company has achieved a reduction of 20% in odor removal efficiency through the addition of deep oxidation odor removal devices in its fermentation and product drying processes[77]. - The company has maintained compliance with national discharge standards, with total emissions not exceeding permitted limits across its subsidiaries[71]. Corporate Governance and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[94]. - The company has not received any non-standard audit opinions for the previous annual report[95]. - The company has not reported any violations or penalties involving its directors, supervisors, senior management, or controlling shareholders during the reporting period[100]. - The company has committed to maintaining independence in operations and adhering to relevant regulations post-restructuring[93]. - The company has outlined its responsibilities regarding the resolution of non-operating debts related to its subsidiary, ensuring that obligations are met according to prior agreements[97]. - The company has confirmed that there are no significant changes in the status of previous litigation matters that were disclosed in temporary announcements[96]. Shareholder and Capital Management - The company completed a share repurchase plan in 2021, repurchasing 34,222,000 shares, which is 1.10% of the total share capital, for a total expenditure of CNY 200,480,500[104]. - As of May 9, 2022, the company had repurchased 26,084,878 shares, representing 0.84% of the total shares, with a total expenditure of CNY 200,201,500[106]. - The company plans to distribute cash dividends of approximately CNY 1.239 billion for the 2021 fiscal year, with a distribution ratio of CNY 4.0 per 10 shares[108]. - The company's registered capital will decrease from CNY 3,098,619,928 to CNY 3,042,465,447 after the completion of share cancellations[111]. - The total number of shares held by the top ten shareholders is 854,103,033, accounting for 27.56% of the total shares[114]. - The repurchase account holds 56,154,481 shares, representing 1.81% of the total share capital, all of which are to be canceled[114]. Legal and Regulatory Matters - There are significant litigation matters involving the company, particularly related to the transfer of equity in a subsidiary, which includes obligations for compensation due to prior debts[95]. - The company is actively monitoring ongoing litigation related to its subsidiary and will pursue legal responsibility if any losses occur[99]. - The company has committed to taking effective measures to avoid engaging in competitive businesses with its subsidiaries after the completion of the major asset restructuring[93].

Financial Performance - The company's operating revenue for Q1 2022 was RMB 6,712,290,632.48, representing a 26.45% increase compared to RMB 5,308,348,754.19 in the same period last year[4]. - Net profit attributable to shareholders reached RMB 1,158,775,246.72, a significant increase of 183.71% from RMB 408,441,231.32 year-on-year[4]. - The net profit after deducting non-recurring gains and losses was RMB 1,136,042,840.95, up 193.39% from RMB 387,215,033.23 in the previous year[4]. - The net cash flow from operating activities improved to RMB 728,205,947.13, a 308.75% increase from a negative RMB 348,842,872.03 in the same period last year[4]. - Basic and diluted earnings per share were both RMB 0.37, reflecting a 184.62% increase compared to RMB 0.13 in the previous year[4]. - The weighted average return on equity rose to 10.35%, up from 4.4% in the same period last year, marking a 5.95% increase[4]. - The gross profit margin improved from 16.47% to 26.24%, contributing to the significant increase in net profit[7]. - Total revenue for Q1 2022 reached ¥6,712,290,632.48, an increase of 26.4% compared to ¥5,308,348,754.19 in Q1 2021[18]. - The net profit for Q1 2022 was CNY 1,158,775,246.72, a significant increase from CNY 414,970,065.30 in Q1 2021, representing a growth of approximately 178.5%[19]. - Operating profit for Q1 2022 reached CNY 1,359,112,502.61, compared to CNY 497,242,044.83 in the same period last year, indicating a year-over-year increase of about 173%[19]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 22,373,434,883.94, a 6.64% increase from RMB 20,921,200,513.89 at the end of the previous year[4]. - Total assets increased to ¥22,373,434,883.94 from ¥20,979,450,562.75, reflecting a growth of 6.6%[18]. - Total liabilities amounted to ¥10,531,409,090.49, up from ¥10,306,761,328.24, indicating an increase of 2.2%[18]. - The company's total liabilities as of March 31, 2022, were CNY 6,964,728,562.82, compared to CNY 6,711,319,376.80 at the end of 2021, an increase of 3.8%[26]. Shareholder Equity and Stock Repurchase - Shareholders' equity attributable to the parent company increased to RMB 11,842,025,793.45, reflecting a 10.96% rise from RMB 10,621,533,338.75 at the end of the previous year[4]. - As of September 28, 2021, the company completed its share repurchase plan, having repurchased 34.22 million shares, accounting for 1.10% of the total share capital[12]. - The total amount spent on the share repurchase was RMB 200.48 million[12]. - The company has repurchased a total of 17.1621 million shares as of the latest announcement, which is 0.55% of the total share capital, with a total expenditure of RMB 120.186 million[13]. - The company plans to cancel 30.0696 million shares from the repurchased stock, reducing its registered capital[12]. - The company’s major shareholders include Meng Qingshan with 854.1 million shares and Chen Zhan with 102.5 million shares[10]. - The company’s stock repurchase plan is in compliance with the regulations of the Shanghai Stock Exchange[13]. Cash Flow and Investment Activities - The cash flow from operating activities for Q1 2022 was CNY 728,205,947.13, a turnaround from a negative cash flow of CNY -348,842,872.03 in Q1 2021[22]. - The total cash outflow from investing activities in Q1 2022 was CNY 974,154,775.39, compared to CNY 578,499,320.80 in Q1 2021, indicating increased investment efforts[22]. - Cash inflow from operating activities totaled CNY 5,090,100,956.01, compared to CNY 3,260,896,894.61 in the same period last year, indicating a year-over-year increase of about 56.1%[31]. - The net cash flow from financing activities was CNY 449,375,431.24, compared to CNY 12,878,677.96 in the same quarter last year, showing a significant increase[32]. Research and Development - Research and development expenses for Q1 2022 were CNY 59,037,845.21, slightly up from CNY 58,177,873.82 in Q1 2021, indicating a focus on innovation[19].